Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A passive dry powder inhaler device comprising a dry powder formulation comprising apomorphine and a metal stearate ~~a pharmaceutically active agent~~, wherein upon actuation of the device, a dosing efficiency at 5μm of at least 70% is achieved.

2. (Original) A device as claimed in claim 1, wherein a dosing efficiency at 3μm of at least 60% is achieved.

3. (Original) A device as claimed in claim 1, wherein a dosing efficiency at 2 μm of preferably at least 40% is achieved.

4. (Currently Amended) A device as claimed in claim 1, wherein the dry powder composition was prepared using a method comprising co-spray drying ~~the~~ apomorphine ~~pharmaceutically active agent~~ with the metal stearate as a force control agent.

5. (Cancelled).

6. (Currently Amended) A device as claimed in claim 4, wherein ~~the~~ apomorphine ~~active agent~~ is spray dried using a spray drier comprising a means for producing droplets moving at a controlled velocity and of a predetermined size.

7. (Original) A device as claimed in claim 6, wherein the spray drier comprises an ultrasonic nebuliser.

8. (Previously presented) A device as claimed in claim 4, wherein the method comprises adjusting the moisture content of the spray dried particles.

9. (Currently Amended) A device as claimed in claim 1, wherein composite active particles for use in the pharmaceutical composition are prepared using a method comprising jet milling apomorphine ~~active~~ particles in the presence of particles of metal stearate as additive material.

10 to 13 (Cancelled).

14. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation is in pre-metered doses stored in one or more foil blisters.

15. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation has a fine particle dose of the emitted dose of at least 70%.

16. (Original) A device as claimed in claim 15, wherein the fine particle dose is at least 80%.

17. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation has a fine particle dose of the metered dose of at least 65%.

18. (Original) A device as claimed in claim 16, wherein the fine particle dose is at least 75%.

19. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation dispensed upon actuation produces a peak blood plasma level within 1 to 20 minutes of pulmonary inhalation.

20. (Original) A device as claimed in claim 19, wherein the peak blood plasma level within 1 to 10 minutes of pulmonary inhalation.

21. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation dispensed upon actuation produces the pharmacodynamic effect within 15 minutes of pulmonary inhalation.

22. (Original) A device as claimed in claim 21, wherein the effect is produced within 10 minutes of pulmonary inhalation.

23. (Original) A device as claimed in claim 21, wherein the effect is produced within 5 minutes of pulmonary inhalation.

24. (Currently Amended) A device as claimed in claim 1, wherein the onset of the effect of ~~the pharmaceutically active agent~~ apomorphine following pulmonary inhalation is twice as fast as the onset of the effect when ~~the~~ apomorphine ~~agent~~ is administered via the oral route.

25. (Original) A device as claimed in claim 24, wherein the onset of the effect is three times faster than that achieved by administration via the oral route.

26. (Original) A device as claimed in claim 24, wherein the onset of the effect is five times faster than that achieved by administration via the oral route.

27. (Original) A device as claimed in claim 24, wherein the onset of the effect is eight times faster than that achieved by administration via the oral route.

28. (Currently Amended) A device as claimed in claim 1, wherein the effect of the dry powder formulation following pulmonary inhalation is such that the dose of ~~the~~ apomorphine ~~pharmaceutically active agent~~ is reduced by at least 50% compared to the dose required to have the same effect when administered via the oral route.

29. (Original) A device as claimed in claim 28, wherein the dose is reduced by at least 70%.

30. (Original) A device as claimed in claim 28, wherein the dose is reduced by at least 80%.

31. (Original) A device as claimed in claim 28, wherein the dose is reduced by at least 90%.

32. (Currently Amended) A device as claimed in claim 1, wherein the administration of the dry powder formulation by pulmonary inhalation does not cause the adverse side effects normally associated with the administration of ~~the~~ apomorphine ~~pharmaceutically active agent~~ via other routes.

33. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation is produced by a micronisation process.

34. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation has a tapped density of more than 0.1g/cc.

35. (Original) A device as claimed in claim 34, wherein the formulation has a tapped density of more than 0.2g/cc.

36. (Original) A device as claimed in claim 34, wherein the formulation has a tapped density of more than 0.5g/cc.

37. (Currently Amended) A device as claimed in claim 1, wherein apomorphine ~~the pharmaceutically active agent~~ has a systemic effect following administration by pulmonary inhalation.

38. (Cancelled)

39. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation is processed without the use of an organic solvent.

40. (Previously presented) A device as claimed in claim 1, wherein the dry powder formulation is dry processed in the absence of any solvent.